Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (9073)	9/9/2003 10:44:43 AM
From: michael_f_murphy	Respond to of 52153

<<Can you name the partners who paraded to Isis>> Novartis bailed in early 2000. As I recall Amgen, Pfizer, and Lilly stayed after that. There may be others. <<I'm asking how it's going to work, from a naive stand. What is known about regulation, an intervention point? >> Doubt if many, if any, people know exactly. Not much that I know :-) Anylam is private, not asking for public trust and John Doe's $$$, in contrast to RNAI. Seems appropriate given the current state of knowledge. Still, an interesting area to watch, if not to invest.